Company Profile
Public information reviewed
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world.
Business, legal identity, ownership structure and classifications.
Sector and industry values retain their source labels. A classification provider, taxonomy version and assignment date are not established unless the cited record states them.
Explore the roles, education and affiliations published in this record.
Start not stated → End not stated
Date not established · source reported
Observed: 2026-09-24
Dashed lines mark past roles. Select a connection to see its dates and sources.
Board leadership, management, committees and their disclosed responsibilities.
Structured records are unavailable. This does not establish that no records exist.
Canonical AEGIS identity graph
Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.
Executive Vice President and President, Lilly Immunology
Executive Vice President, General Counsel and Secretary
Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Laboratories
Chair, President, and Chief Executive Officer (CEO)
Executive Vice President and President, Manufacturing Operations
Executive Vice President, Chief People Officer
Executive Vice President and President, Lilly USA and Global Customer Capabilities
Executive Vice President, President, Lilly Oncology and Head of Corporate Business Development
Executive Vice President and President, Lilly Cardiometabolic Health
Executive Vice President and Chief Financial Officer
Executive Vice President, Global Quality
Executive Vice President and President, Lilly International
Governance leadership
Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.
Record as of Sep 24, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.
Reported statements, original filings and proxy disclosures with their reporting periods.
Structured records are unavailable. This does not establish that no records exist.
Structured records are unavailable. This does not establish that no records exist.
Structured records are unavailable. This does not establish that no records exist.
Ownership, funding and dated financial information.
Structured records are unavailable. This does not establish that no records exist.
Ownership disclosures retain their reporting dates and source types. Economic ownership, investment discretion and voting authority are distinct. Activism and settlement-dated short interest are not established by holdings or short-sale volume.
Disclosed coverage, ratings and assurance scope.
Structured records are unavailable. This does not establish that no records exist.
Credit-rating evidence, where published, appears in the Governance and Basis sections with its source and reporting date. Insurance coverage, cyber ratings and assurance reports require their own issuer, scope, date and usage rights. Indemnification does not establish insurance coverage.
Structured records are unavailable. This does not establish that no records exist.
Structured records are unavailable. This does not establish that no records exist.
Identifiers, sources and record limitations.
